Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
Ensysce Biosciences宣布，该公司可能会继续在纳斯达克资本市场层面上市，并将延期至2024年5月13日，以证明其遵守了上市规则5550 (b) (1) 中的股权要求
Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).
应用变革性化学提高处方药安全性的临床阶段公司Ensysce Biosciences, Inc.（“公司”）（纳斯达克股票代码：ENSC）今天宣布，它已收到纳斯达克股票市场有限责任公司（“纳斯达克”）的通知，如2024年2月26日的决定所述，该公司可能会继续在纳斯达克资本市场层面上市，并将延期至2024年5月13日，以证明合规性符合《上市规则》第5550 (b) (1) 条的股权要求。